KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non Operating Income: 2014-2024

Historic Non Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to $103.9 million.

  • CRISPR Therapeutics AG's Non Operating Income rose 4.68% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.8 million, marking a year-over-year decrease of 6.36%. This contributed to the annual value of $103.9 million for FY2024, which is 44.68% up from last year.
  • CRISPR Therapeutics AG's Non Operating Income amounted to $103.9 million in FY2024, which was up 44.68% from $71.8 million recorded in FY2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Non Operating Income peaked at $103.9 million during FY2024, and registered a low of $6.0 million during FY2021.
  • In the last 3 years, CRISPR Therapeutics AG's Non Operating Income had a median value of $71.8 million in 2023 and averaged $66.1 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Non Operating Income slumped by 75.50% in 2020, and later soared by 277.49% in 2022.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Non Operating Income stood at $6.4 million in 2020, then dropped by 5.89% to $6.0 million in 2021, then spiked by 277.49% to $22.7 million in 2022, then soared by 216.91% to $71.8 million in 2023, then skyrocketed by 44.68% to $103.9 million in 2024.